Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**glucagon + oxymetazoline** is a theoretical combination drug comprising **glucagon** and **oxymetazoline**. Glucagon is a peptide hormone used as an emergency treatment for severe hypoglycemia; it increases blood glucose by stimulating hepatic glucose production via activation of the glucagon receptor. Oxymetazoline is a small molecule alpha-adrenergic agonist used as a topical nasal decongestant and vasoconstrictor; it acts on alpha-1A, alpha-2A, alpha-2B, and other adrenergic receptors to cause vasoconstriction and reduce symptoms of nasal congestion, facial erythema, and ptosis[1][2]. No known marketed or clinically investigated product combines these two substances as a single drug; there are no identified clinical indications or manufacturers for this combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glucagon + oxymetazoline.